semaglutide and perimenopause Hormone Therapy: What Perimenopausal Patients Should Know Postmenopausal women on the GLP-1

Furthermore, GLP-1 acts on central nervous system receptors in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala to promote satiety and reduce food intake (Turton et al 1996) (Fig

Semaglutide is a glucagon-like peptide-1 agonist that works on the GLP-1 receptors in the body to reduce appetite by delaying gastric emptying

Heidi Queen blends the science of modern medicine with a preventive, root-cause mindset

While oral forms can support general antioxidant function, their impact on skin tone varies greatly between individuals due to how the body absorbs and metabolises them

In medical settings, dosing decisions depend on: Body weight and composition Insulin sensitivity Baseline IGF-1 levels Growth hormone axis function Medical history Risk factors for hypoglycemia Unlike standard supplements, IGF-1 is a potent signaling molecule that influences glucose metabolism and cellular proliferation

However, structured cycling with breaks is recommended to maintain receptor sensitivity